DE3769812D1 - Verwendung von phosphordiesteraseinhibitoren und cyclischen nukleotidanalogen zur herstellung eines arzneimittels zur stimulierung der traenensekretion. - Google Patents

Verwendung von phosphordiesteraseinhibitoren und cyclischen nukleotidanalogen zur herstellung eines arzneimittels zur stimulierung der traenensekretion.

Info

Publication number
DE3769812D1
DE3769812D1 DE8787301403T DE3769812T DE3769812D1 DE 3769812 D1 DE3769812 D1 DE 3769812D1 DE 8787301403 T DE8787301403 T DE 8787301403T DE 3769812 T DE3769812 T DE 3769812T DE 3769812 D1 DE3769812 D1 DE 3769812D1
Authority
DE
Germany
Prior art keywords
phosphordiesteras
tenary
nucleotid
analogs
secretion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8787301403T
Other languages
English (en)
Inventor
Jeffrey P Gilbard
Darlene A Dartt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eye Research Institute of the Retina Foundation
Original Assignee
Eye Research Institute of the Retina Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eye Research Institute of the Retina Foundation filed Critical Eye Research Institute of the Retina Foundation
Application granted granted Critical
Publication of DE3769812D1 publication Critical patent/DE3769812D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE8787301403T 1986-02-19 1987-02-18 Verwendung von phosphordiesteraseinhibitoren und cyclischen nukleotidanalogen zur herstellung eines arzneimittels zur stimulierung der traenensekretion. Expired - Fee Related DE3769812D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/830,997 US4753945A (en) 1986-02-19 1986-02-19 Stimulation of tear secretion with phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
DE3769812D1 true DE3769812D1 (de) 1991-06-13

Family

ID=25258069

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787301403T Expired - Fee Related DE3769812D1 (de) 1986-02-19 1987-02-18 Verwendung von phosphordiesteraseinhibitoren und cyclischen nukleotidanalogen zur herstellung eines arzneimittels zur stimulierung der traenensekretion.

Country Status (4)

Country Link
US (1) US4753945A (de)
EP (1) EP0234854B1 (de)
JP (1) JPH0788311B2 (de)
DE (1) DE3769812D1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938965A (en) * 1987-07-22 1990-07-03 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government Ocular delivery of prophylactic agents
US4975428A (en) * 1988-05-31 1990-12-04 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors
EP0406210B1 (de) * 1989-06-29 1995-09-27 Washington University Ophthalmikum
CA2052193A1 (en) * 1990-09-28 1992-03-29 Norio Takasugi Topical powder composition containing cyclic amp derivative
US5545617A (en) * 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US6921755B2 (en) * 1998-02-06 2005-07-26 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
US6696425B2 (en) * 1997-02-06 2004-02-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
WO2000038690A2 (en) 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Prostaglandin e agonists for treatment of dry eye
JP4591728B2 (ja) * 1998-12-28 2010-12-01 大正製薬株式会社 眼精疲労改善用点眼剤
US8501911B2 (en) * 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
JP5620037B2 (ja) * 1999-02-24 2014-11-05 ノース・キャロライナ・ステイト・ユニヴァーシティ 粘液分泌を変化させる方法および組成物
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
AU3612600A (en) 1999-02-26 2000-09-14 Inspire Pharmaceuticals, Inc. Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof
US6458854B2 (en) 1999-11-09 2002-10-01 Alcon Universal Ltd. Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
AU1226001A (en) 1999-11-09 2001-06-06 Alcon Universal Limited Phospholipids of hydroxyeicosatetraenoic acid-like derivatives
WO2001034554A1 (en) 1999-11-09 2001-05-17 Alcon Universal Ltd. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
EP1228027B1 (de) 1999-11-09 2004-05-06 Alcon Inc. Tri-heteroatom-substituierte und zwei kohlenstoff homologe von 15-hete und verfahren zur verwendung
TR200201251T2 (tr) 1999-11-09 2002-11-21 Alcon, Inc. Omega zinciri tadil edilmiş 15-hidroksieikosatetraenoik asit türevleri ve bunların göz kurumasının iyileştirilmesi için kullanım yöntemleri
PL356093A1 (en) 1999-11-09 2004-06-14 Alcon Inc. Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders
ATE292464T1 (de) 1999-11-09 2005-04-15 Alcon Inc Heteroatomunterbrochene analoge von15- hydroxyeicosatetraensäure und verfahren zu deren verwendung
US6803385B2 (en) 1999-11-09 2004-10-12 Alcon, Inc. Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
BR0015404A (pt) 1999-11-09 2002-06-25 Alcon Inc Compostos relacionados com ácido 15-hidroxieicosatetraenóico e métodos de uso
WO2001034550A2 (en) 1999-11-09 2001-05-17 Alcon Universal Ltd. 15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders
BR0015392A (pt) 1999-11-09 2002-06-25 Alcon Inc Lipoxina a4 e seus análogos para o tratamento de olho ressecado
ATE296792T1 (de) 1999-11-09 2005-06-15 Alcon Inc Benzenoidderivate von 15- hydroxyeicosatetraensäure und verfahren zur verwendung zur behandlung des trockenen auges
US6552084B2 (en) 1999-11-09 2003-04-22 Alcon Universal Ltd. Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
AU1101301A (en) 1999-11-09 2001-06-06 Alcon Universal Limited 2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use
AU1731101A (en) 1999-12-07 2001-06-18 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
WO2001046134A1 (en) 1999-12-22 2001-06-28 Alcon Universal Ltd. 6-KETO PROSTAGLANDIN F1α AND ANALOGS FOR TREATING DRY EYE
US7919469B2 (en) * 2000-02-24 2011-04-05 North Carolina State University Methods and compositions for altering mucus secretion
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US7524511B1 (en) * 2000-07-12 2009-04-28 Rogue Valley Natural Springs, Inc. Method and kit for moisturizing the surface of the eye
PT1304991E (pt) * 2000-07-12 2014-12-09 Rogue Valley Natural Springs Inc Método e kit para a hidratação da superfície do olho
WO2002034258A1 (en) 2000-10-23 2002-05-02 Alcon, Inc. Use of hydroxyeicosatetraenoic acid derivatives in intraocular surgery
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
WO2003030894A1 (en) * 2001-10-11 2003-04-17 Alcon, Inc. Methods for treating dry eye
WO2003030892A1 (en) * 2001-10-11 2003-04-17 Alcon, Inc. Methods for treating dry eye
US20030109509A1 (en) * 2001-10-11 2003-06-12 Alcon, Inc. Methods for treating dry eye
ATE455758T1 (de) 2001-12-20 2010-02-15 Merck Serono Sa Pyrrolidin-derivatie als prostaglandin- modulatoren
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
DK2020243T3 (en) * 2002-05-28 2018-11-19 Astrazeneca Ab Pharmaceutical composition which can be applied topically
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
CA2497977A1 (en) * 2002-09-20 2004-04-01 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
WO2004060274A2 (en) * 2002-12-20 2004-07-22 Alcon, Inc. Treatment of dry eye by restoring 15-lipoxygenase activity to ocular surface cells
EP1606261B1 (de) 2003-03-10 2009-11-04 Nycomed GmbH Neues verfahren zur herstellung vonroflumilast
US7488713B2 (en) * 2004-03-18 2009-02-10 University Of South Florida Cancer treatment using C-type natriuretic peptides
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050208102A1 (en) * 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US9216106B2 (en) * 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
CA2559853A1 (en) * 2004-02-17 2005-10-13 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
US8759317B2 (en) * 2004-03-18 2014-06-24 University Of South Florida Method of treatment of cancer using guanosine 3′, 5′ cyclic monophosphate (cyclic GMP)
MX2007008744A (es) * 2005-01-20 2008-03-10 Biomarck Pharmaceuticals Ltd Inhibidores de hipersecrecion de mucina con base en la estructura de mans ymetodos de uso.
JP5383183B2 (ja) * 2005-03-16 2014-01-08 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング ロフルミラストを含有する矯味された剤形
US7247623B2 (en) * 2005-08-19 2007-07-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with non-drying antihistamines
US20070207116A1 (en) * 2006-03-01 2007-09-06 Brown David C Antioxidant compositions for the eye
WO2007130672A2 (en) * 2006-05-05 2007-11-15 University Of South Florida Urodilatin cancer treatment
ZA200900550B (en) * 2006-07-26 2010-03-31 Biomarck Pharmaceuticals Ltd Methods for attenuating release of inflammatory mediators and peptides useful therein
US7825092B2 (en) * 2006-08-08 2010-11-02 University Of South Florida Dendroaspis natriuretic peptide for treatment of cancer
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
US20150031712A1 (en) 2013-03-12 2015-01-29 Moshe Rogosnitzky Therapeutic Compositions Containing Dipyridamole and Treatment Packs Including Such Compositions and Methods for Producing Same
DE102014203152A1 (de) * 2014-02-21 2015-08-27 Ursapharm Arzneimittel Gmbh Mikro- oder Nanoemulsion zur ophthalmologischen Anwendung
US10322129B2 (en) 2015-06-08 2019-06-18 O.D. Ocular Discovery Ltd. Therapeutic compositions containing dipyridamole, treatment packs and kits including such compositions and methods for producing same
BR112021000940B1 (pt) 2018-11-09 2023-05-02 Nippon Steel Stainless Steel Corporation Chapa de aço inoxidável ferrítico

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE897492C (de) * 1943-11-02 1953-11-23 Ruhrchemie Ag Automatische Gas-Dauerprobenahme-Apparatur mit regelbarer Dosierung
NL247008A (de) * 1959-07-22 1900-01-01
GB1561037A (en) * 1976-07-15 1980-02-13 Cehovic G Composition for the treatment and prevention of skin eye and mucosal inflammation
FR2358155A1 (fr) * 1976-07-15 1978-02-10 Lapinet Eugene Composition pour le traitement et la prevention de l'irritation et de l'inflammation de la peau, de l'oeil et des muqueuses
US4208408A (en) * 1978-03-06 1980-06-17 Sandoz, Inc. Substituted 1-oxa-4-aza-2,6-disilacyclohexanes
CA1165241A (en) * 1980-05-06 1984-04-10 Bristol-Myers Squibb Company Sustained release theophylline tablet having reduced bulk
IT1200944B (it) * 1982-08-10 1989-01-27 Malesci Sas Derivati xantinici,procedimento per la loro preparazione,composizione farmaceutiche che il contengono e loro impiego terapeutico
US4559343A (en) * 1982-09-07 1985-12-17 Alcon Laboratories, Inc. Nonirritating aqueous ophthalmic compositions comfort formulation for ocular therapeutic agents
JPH0729927B2 (ja) * 1983-04-09 1995-04-05 日研化学株式会社 テオフィリン徐放性製剤
US4478822A (en) * 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4717713A (en) * 1983-10-31 1988-01-05 Research Corporation Controlled release liquid pharmaceutical
IE58246B1 (en) * 1984-12-21 1993-08-11 Byk Gulden Lomberg Chem Fab Theophylline sustained release formulation

Also Published As

Publication number Publication date
JPS62246524A (ja) 1987-10-27
EP0234854A3 (en) 1987-11-19
US4753945A (en) 1988-06-28
JPH0788311B2 (ja) 1995-09-27
EP0234854A2 (de) 1987-09-02
EP0234854B1 (de) 1991-05-08

Similar Documents

Publication Publication Date Title
DE3769812D1 (de) Verwendung von phosphordiesteraseinhibitoren und cyclischen nukleotidanalogen zur herstellung eines arzneimittels zur stimulierung der traenensekretion.
DE3585607D1 (de) Verwendung von paroxetine zur herstellung eines arzneimittel zur behandlung von obesitaet.
ATA68386A (de) Verwendung von 3'-azido-3'-desoxythymidin oder eines pharmazeutisch annehmbaren derivats hievon zur herstellung von medikamenten
DE3856306D1 (de) Verfahren zur Herstellung von Applikatoren zur transdermalen Verabreichung von Medikamenten
DE244380T1 (de) Arzneiformulierungen saeurelabiler substanzen zur oralen verwendung.
ATE126433T1 (de) Verwendung von gamma-hydroxy-buttersäuresalzen zur herstellung von pharmazeutischen zusammensetzungen zur verwendung bei der behandlung von alkoholismus und die hergestellten zusammensetzungen.
DE3650700D1 (de) Verwendung eines Massbandes zur Direktbestimmung von Parametern für die physikalische Therapie und physiologischer Grössen
DE3484055D1 (de) Verwendung von ubidecarenon zur herstellung eines medikaments zur behandlung von durch radiotherapie hervorgerufenen geschwueren.
ATA243992A (de) Verfahren zur herstellung von zur selektiven senkung des blutlipoidspiegels geeigneten arzneimittelpräparaten
DE3785740D1 (de) Verwendung von carboxamid-verbindungen zur herstellung eines arzneimittels zur behandlung der hyperlipaemie.
PT83186A (de) Verfahren zur herstellung einer stabilen modifikation von torasemid sowie arzneimittel enthaltend torasemid
DE68924714D1 (de) Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen.
PT81531A (de) Verfahren zur herstellung von isosilybinfreiem silibinin und araneimittel enthaltend silibinina
PT81829A (de) Traegermatrix zur aufnahme von katalytisch wirkenden verbindungen und verfahren zur herstellung der traegermatrix
DE3781054D1 (de) Die verwendung von d-fenfluramin zur herstellung von arzneimitteln, zur behandlung von depressionen.
DE3768150D1 (de) Verwendung eines 1,3-oxazolidin-2-on-derivates zur herstellung eines arzneimittels zur behandlung von ischaemie.
DE68905657D1 (de) Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen.
DE3686097D1 (de) Verwendung von dopamin-agonisten zur herstellung eines arzneimittels zur behandlung von psychostimulant-sucht.
ATA327685A (de) Verfahren zur herstellung eines neuen lymphokins (lk 2) sowie verwendung von lk 2 zur herstellung eines pharmazeutischen praeparates
DE3873210D1 (de) Verwendung von benzylpyridin-derivaten zur herstellung eines arzneimittels zur behandlung der demenz.
DE3873188D1 (de) Verwendung von nigerizin zur herstellung eines mittels zur behandlung von virus-erkrankungen.
DE3578374D1 (de) Verwendung von chinolonen fuer die herstellung eines arzneimittels zur behandlung von herzerkrankungen.
DE3483944D1 (de) Verwendung von selektiv peripheren dopamin-antagonisten zur herstellung eines arzneimittels zur topischen behandlung von okularer hypertension.
DE3777709D1 (de) Verwendung von 3'azido-3'deoxythymidin zur herstellung eines arzneimittels zur behandlung von gardiasis.
DE3788491D1 (de) Energiehärtbare druckempfindliche Klebstoffe und Verfahren zur Herstellung von druckempfindlichen Klebstoffen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee